BASF adopts RSPO sustainable palm oil model

ACI expects healthcare antiseptic manufacturers to lose most active ingredients
The US Food and Drug Administration (FDA) will ban some 80% of active ingredients currently allowed for use in healthcare antiseptics, the American Cleaning Institute (ACI) expects.
Plans to require manufacturers to submit data demonstrating the safety and efficacy of their antibacterial ingredients were set out in a 2015 proposed rule - and are expected to become law when the final rule is issued. The FDA will assess data submitted by industry and decide whether to classify actives as "generally recognised as safe and effective" (Gras/Grae), or ban their use in the products.
Triclosana href='https://www.echemi.com/products/pid_Seven3714-triclocarban.html'>Triclocarban.
ACI expects triclosan to face a ban in healthcare products as well, along with more than 20 other ingredients, its associate vice president for environmental safety, Paul DeLeo, told CW+BiocidesHub.
Some substances will be banned due to a lack of support by industry, he said. "Companies know it won't get FDA approval so they are not willing to do the additional testing the agency is requiring."
Others will fail because the data to support them is too challenging to generate. The agency, he says, is asking for "new methods that we are not aware of anyone having successfully completed in this space", but it has been willing to give companies more time.
2026-10-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF and Evonik Rumored Potential Acquisition or Merger
-
BASF and Thailand’s NEO Corporate Enter Joint Development Partnership in Personal Care
-
BASF Raises North American Nylon Products by $0.08/lb, Fourth Price Increase in Six Months
-
First New UV Filter in Nearly 27 Years: BASF's Tinosorb® S Approved by FDA, Marking a Historic Shift for the U.S. Sunscreen Market
-
Multiple Chemical Industry Leaders Post Strong H1 Earnings Growth as Sector Profitability Revives
-
The Crop Protection Patent Cliff Is Here
-
BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync
-
EU Clears Carlyle's Acquisition of BASF's Coatings Business, but Demands Divestment of Nouryon's Polysulfide Assets: What Are the Underlying Risks?
-
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
BASF Launches Global Expansion Plan for Aroma Ingredients
Recommend Reading
-
Clariant and FUHUA Establish Joint Venture to Co-Develop Halogen-Free Flame Retardants
-
“Falling Revenue, Soaring Profits”: Is AkzoNobel’s Financial Alchemy Real Muscle—or Just Smoke and Mirrors?
-
Givaudan to Build New Fragrance Compounding Facility in Pedro Escobedo, Mexico
-
Can the Manufacturing Sector Withstand Dow’s April Polyethylene Price Doubling?
-
OCI Exits TDI Business and Joins South Korean Semiconductor Materials Cluster on the Same Day
-
Business Society’s Market Outlook for Ethylene Glycol on September 3, 2026: Clearly Upward Trend
-
Business Society’s Trend Analysis for Maleic Anhydride on September 11, 2026: Fluctuating with a Slight Bullish Bias
-
Business Society September 24, 2026 Aniline Trend Analysis: Rising from High Levels
-
Suppliers Hold Firm on Prices, Slight Increase in Butadiene Market in China
-
Business Society September 30, 2026 Isooctanol Trend Analysis: Strong Rebound with a Bullish Bias